European regulator approves Ozempic label update to include kidney disease benefits

The European Medicines Agency has approved Novo Nordisk's request to update the label for its diabetes drug Ozempic. The new label will include information on the drug's ability to reduce the risk of kidney disease progression. This update follows a trial showing that semaglutide, the active ingredient in Ozempic, can help prevent kidney disease. Novo Nordisk is also awaiting a decision on a similar label update for Ozempic in the United States, expected in early 2025.